Clinipace LTD   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Morrisville NC United States (2003)

Organization Overview

First Clinical Trial
2011
NCT01336530
First Marketed Drug
2013
phenylephrine (Prefrin)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Clinipace Worldwide

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Calcinosis (Phase 2)

Cardiovascular Abnormalities (Phase 2)

Cardiovascular Diseases (Phase 2)

Communicable Diseases (Phase 3)

Esophagitis (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Infections (Phase 3)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Respiration Disorders (Phase 2)

Respiratory Tract Diseases (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Vascular Calcification (Phase 2)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 22